Peplix is a startup company based in Brisbane
Australia. The near term goal of the company is to demonstrate its
technology is the best available for making peptide helix mimetics.
About the Founder
Peter Cassidy is an organic and medicinal chemist with expertise in the development of peptide mimetics. Peplix is his second company.
Peter
completed his PhD studies at the University of Queensland with Professor Paul
Alewood.
During his
doctoral work the patent Peptide
Turn Mimetics was filed in collaboration with the University of Queensland. After completing his PhD Peter partnered with
the University to commercialise the technology – founding the company Mimetica
in 2001. Over the next few years
Mimetica expanded and focused on optimising its lead compound series. Patents were filed in 2008 covering the
developed compounds.
Peter left Mimetica
at the end of 2008 when the company decided to cease medicinal chemistry and focus
on developing a compound for topical application. This compound has advanced through
pre-clinical and scale-up and completed an initial Phase II Human Clinical trial
in 2012.
While at
Mimetica Dr Cassidy collaborated with Paul Alewood to examine the application
of some mimetica chemistry to making helix mimetics. This work has been published, this earlier work does not form
part of the Peplix technology.
